Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01707992 · ClinicalTrials.gov registry record · Phase 3
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,199
- Enrollment target
NCT01707992 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 2,199 participants.
The verdict
NCT01707992, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,199 participants
- Enrollment target
Study Summary
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod in participants with RRMS. The study has 2 periods: Period 1, the double-blind, placebo-controlled period (up to 24 months) and Period 2, the active treatment period (24 months).
Interventions
- DRUG Placebo
- DRUG Laquinimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,199 participants |
| Start Date | 2013-02-20 |
| Est. Completion | 2017-07-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01707992
The ClinicalTrials.gov registry entry for NCT01707992 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01707992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01707992 about?
NCT01707992 is a clinical study titled "The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)". This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod in participants with RRMS. The study has 2 periods: Period 1, the...
What is the current status of trial NCT01707992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,199 participants. The study started on 2013-02-20. Estimated completion is 2017-07-04.
What interventions are being tested in trial NCT01707992?
The interventions under investigation include: Placebo (DRUG), Laquinimod (DRUG).
Who is sponsoring clinical trial NCT01707992?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.